Abstract
Octadecyl-[2-(N-methylpiperidinio)ethyl]-phosphate (OMPEP, D-20133), a heterocyclic analogue of hexadecylphosphocholine (MIL), has been synthesized in an attempt to increase the therapeutic range of the parent compound. The antineoplastic activity of the novel alkylphospholipid was compared with that of MIL in dimethylbenz(a)anthracene-induced mammary carcinoma of the rat. Using tumors of different sizes and repeated daily doses as well as high single doses, we achieved marked remissions with either compound. However, the therapeutic range of OMPEP was broader than that of the parent drug. Furthermore, the emetic potential of OMPEP tested on ferrets was distinctly less pronounced than that of MIL. In vitro the new alkylphospholipid proved to be more active than MIL in all cell lines tested, and its differentiation-inducing capacity turned out to be superior to that of MIL. No hematological toxicity was observed at various OMPEP doses during a 3-week treatment period.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barlow RB (1964) Introduction to chemical pharmacology. Methuen Ltd. London
Berger MR, Muschiol C, Schmähl D, Unger C, Eibl H (1987) Chemotherapeutische Studien zur Strukturwirkungsbeziehung zytotoxischer Alkyllysophospholipide an chemisch induzierten Mammakarzinomen der Ratte: In: Unger C, Eibl H, Nagel GA (eds) Die Zellmembran als Angriffspunkt der Tumortherapie. Zuckerschwerdt, München, p 27
Danhauser-Riedl S, Drozd A, Zaffernai M, Bruntsch U, Peukert M, Sindermann H, Präuer HW, Siewert JR, Rastetter J, Berdel WE (1991) Phase I study of weekly oral miltefosine (hexadecylphosphochole) in cancer patients. Onkologie 14:392
Florczyk AP, Schurig JE, Bradner WT (1982) Cisplatin-induced emesis in the ferret; a new animal model. Cancer Treat Rep 66:187
Hilgard P, Stekar J, Voegeli R, Engel J, Schumacher W, Eibl H, Unger C, Berger MR (1988) Characterization of the antitumor activity of hexadecylphosphocholine (D-18506). Eur J Cancer 24: 1457
Hilgard P, Stekar J, Voegeli R, Harleman JH (1992) Experimental therapeutic studies with miltefosine in rats and mice. In: Eibl H, Hilgard P, Unger C (eds) Alkylphosphocholines: new drugs in cancer therapy. Karger, Basel, p 116
Hilgard P, Klenner T, Stekar J, Unger C (1993) Alkylphosphocholines: a new class of membrane active anticancer agents. Cancer Chemother Pharmacol (in press)
Kosano H, Takatani O (1988) Reduction of epidermal growth factor binding in human breast cancer cell lines by an alkyllysophospholipid. Cancer Res 48:6033
Maurer HR, Echarti C (1990) Clonogenic assays for hematopoietic and tumor cells using agar-containing capillaries. In: Polland JW, Walker JM (eds) Methods in molecular biology, vol 5. Animal cell culture. Humana, Clifton, New Jersey, p 379
Maurer HR, Hilgard P (1992) Induction of tumor cell differentiation by alkylphospholipids: a new approach for in vitro screening. In: Eibl H, Hilgard P, Unger C (eds) Alkylphosphocholines: new drugs in cancer therapy. Karger, Basel, p 90
Maurer HR, Echarti C, Voegeli R, Pohl J, Hilgard P (1993) The antitumor activity of D-17872 is associated with tumor cell differentiation. Cancer Chemother Pharmacol (in press)
Muschiol C, Berger MR, Schuler B, Scherf HR, Garzon FT, Zeller WJ, Unger C, Eibl HJ, Schmähl D (1987) Alkylphosphocholines: toxicity and anticancer properties. Lipids 22:930
Salmon SE, Hamburger AW, Soehnlen B, Durie BGM, Alberts DS, Moon TE (1978) Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs. N Engl J Med 298:1321
Stekar J, Schumacher W, Nößner G, Kutscher B (1992) D-20133, a novel alkylphospholipid with high antineoplastic activity. J Cancer Res Clin Oncol [Suppl] 118:R83
Voegeli R, Echarti C, Rainer HR, Stekar J, Hilgard P, Unger C (1993) Selective cytostatic activity of hexadecylphosphocholine in vitro leads to the establishment of an in vivo screening system for phospholipid analogues. Int J Oncol 2:161
Author information
Authors and Affiliations
Additional information
The first author dedicates this work to the memory of Tone Slivnik
Rights and permissions
About this article
Cite this article
Stekar, J., Hilgard, P., Voegeli, R. et al. Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid, D-20133. Cancer Chemother. Pharmacol. 32, 437–444 (1993). https://doi.org/10.1007/BF00685887
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685887